Stryker Announces Exclusive Collaboration With RegenLab

Stryker RegenKit®-THT Offers Safe and Rapid Preparation of Autologous Platelet-Rich Plasma (A-PRP)

08 Jul, 2011, 10:00 ET from Stryker Orthopaedics

SAN DIEGO, July 8, 2011 /PRNewswire/ -- Stryker Joint Preservation, a business unit of Stryker's Orthopaedics group, today announced at the 2011 American Orthopaedic Society for Sports Medicine meeting that it has entered into an exclusive collaboration with RegenLab SA to distribute Stryker's RegenKit-THT, a one-step system designed for the safe and rapid preparation of autologous platelet-rich plasma (A-PRP) from a small sample of blood at the patient's point of care.

A-PRP contains an increased concentration of platelets, while maintaining physiological levels of leukocytes (white blood cells).  When activated, platelets have been found to release growth factors which may participate in the healing process, and a multitude of proteins and bioactive factors critical to the healing process and the recruitment of cells.  Leukocytes are responsible primarily for defending the body against infection, but are also key players during the initial inflammation phase of tissue healing.

In comparison to competitive offerings, the A-PRP prepared using Stryker's RegenKit-THT provides the highest platelet recovery and viability(1), while its simplified single tube preparation, with a minimal eight minute centrifuge spin time and reduced number of steps, helps maximize efficiency in the office and O.R.

"The RegenKit-THT system is the result of 10 years of scientific research in tissue regeneration and is designed to provide an autologous and physiological solution to promote a biological environment for regenerative cells enrichment.  RegenLab is pleased to collaborate with Stryker, a leader in medical technologies and innovation, which will allow for the widespread distribution of our A-PRP technology," said Antoine Turzi, Founder and CEO of RegenLab SA.

"The addition of the RegenKit for PRP therapy to Stryker's Joint Preservation Biologics portfolio allows us to provide surgeons with this emerging therapy for orthopaedic applications.  We're pleased to collaborate with RegenLab on the distribution of this system," said Matt Moreau, Vice President & General Manager, Stryker Joint Preservation.

To see a demonstration of this product, please visit Stryker at booth #503 at AOSSM.

About Stryker Orthopaedics

Stryker Orthopaedics is a division of the Stryker Corporation, one of the world's leading medical technology companies. Stryker Orthopaedics offers an extensive orthopaedic product portfolio including hip, knee and upper extremity reconstructive devices, bone cement, trauma implants, bone substitutes, joint preservation products and spine systems. For more information about Stryker Orthopaedics, visit: http://www.stryker.com/en-us/products/Orthopaedics/index.htm

About Stryker

Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.

(1) Study Report – Regen™ THT Tube Performance Testing, USFDA 510(k) BK090048, May 2010, Data on file at RegenLab, Switzerland.

NL11-FB-CO-1532

Contact:

Jeanine Guilfoyle


Stryker Orthopaedics


201-831-6277


jeanine.guilfoyle@stryker.com



SOURCE Stryker Orthopaedics



RELATED LINKS

http://www.stryker.com